Why is ASX 200 stock Telix Pharmaceuticals suddenly so hot?

Why are the shares of this biotechnology rising so much lately?

| More on:
Woman receiving radiation therapy for cancer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The shares of this ASX 200 healthcare stock have risen more than 30% in a month 
  • The company delivered a 27% lift in revenue in the first quarter of this year 
  • Sales growth of Illuccix in the United States has helped boost revenue 

ASX 200 stock Telix Pharmaceuticals Ltd (ASX: TLX) has been having a top run on the market lately.

Telix shares have risen nearly 32% in a month and are currently fetching $9.30. In today's trade, Telix shares are up 4.44%. In contrast, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.31% today.

Let's take a look at what has been weighing on the Telix share price recently.

What is going on?

Telix is a global clinical-stage biotechnology developing targeted radiation therapy to treat cancer.

Investors appear to have reacted to multiple price-sensitive updates delivered to the market in the last month.

Telix recently revealed its customer receipts lifted 15% during the first quarter of 2023 to $83.2 million. Revenue rose 27% to $100.1 million.

A major highlight of these results was news that the US market demand for the company's Illuccix diagnostic imaging agent for prostate cancer is continuing to grow. Revenue from US sales of Illuccix rose 27% quarter on quarter to $97.5 million. This follows the US Food and Drug Administration (FDA) expanding the label indication for Illuccix as advised in March.

On 17 April, Telix announced the successful preclinical development of radiolabelled Olaratumab. This is an antibody licenced from Eli Lilly and Company (Lilly). The company said:

Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation.

Telix will now progress to first-in-human clinical studies based on these highly encouraging results.

In early April, Telix shares rose amid progress on making Illuccix available in the UK and Europe. Illuccix is already approved for use in Australia, the United States, New Zealand and Canada. Telix filed a Marketing Authorisation Application (MAA) for Illuccix in the United Kingdom.

Telix also noted it is processing a separate MAA application for the European Union. The company's EMEA CEO Raphael Ortiz said:

Telix is committed to ensuring widespread access to commercially available gallium-based PSMA-PET imaging across the EU and UK.

Telix share price snapshot

The Telix Pharmaceuticals share price has returned 91% in the last year.

Created with Highcharts 11.4.3Telix Pharmaceuticals PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

This ASX 200 stock has a market capitalisation of about $2.9 billion.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »